Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 451-460 of 2762 for cancer

Edit search filters
  1. A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label

    Rochester, MN

  2. A Study to Evaluate TAB006, as Monotherapy and in Combination with Toripalimab, in Patients with Previously Treated, Advanced Malignancies

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. Dose Escalation Study of mRNA 2416 for Intratumoral Injection to Patients With Advanced Malignancies

    Scottsdale/Phoenix, AZ

  4. A Study to Determine Immune System Response in Newly Diagnosed Lymphoma Patients Starting First Line Therapy

    Rochester, MN

  5. A Study of the Safety and Effectiveness of HBI-8000 with Nivolumab to Treat Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

  6. S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

    Mankato, MN

  7. NRG-GY012 “A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5356 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women with Recurrent or Persistent Endometrial Cancer”

    Eau Claire, WI, Scottsdale/Phoenix, AZ, Rochester, MN

  8. Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

    Rochester, MN, Scottsdale/Phoenix, AZ

  9. Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)

  10. Ruxolitinib in Combination with Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer